|
Malignant neoplasm of breast
|
0.560 |
Biomarker
|
disease |
BEFREE |
We investigated whether vitamin D receptor (<i>VDR</i>) polymorphisms were associated with cancer biomarkers, i.e., E-cadherin, matrix metallopeptidase 9 (MMP9), interferon β (IFNβ), soluble intercellular adhesion molecule-1 (s-ICAM-1), soluble vascular cell adhesion molecule-1 (s-VCAM-1), tumor necrosis factorα (TNFα), interleukin 6 (IL6), plasminogen activator inhibitor-1(PAI-1), and human high sensitivity C-reactive protein (hs-CRP), among breast cancer survivors who received vitamin D3 supplementation.
|
31167402 |
2019 |
|
Malignant neoplasm of breast
|
0.560 |
Biomarker
|
disease |
BEFREE |
These results indicate that a combination treatment of UCMS-IFN-beta cells and 5-FU is a potentially effective therapeutic procedure for breast cancer.
|
18608205 |
2008 |
|
Malignant neoplasm of breast
|
0.560 |
Therapeutic
|
disease |
CTD_human |
These results indicate that a combination treatment of UCMS-IFN-beta cells and 5-FU is a potentially effective therapeutic procedure for breast cancer.
|
18608205 |
2008 |
|
Malignant neoplasm of breast
|
0.560 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
|
Malignant neoplasm of breast
|
0.560 |
Biomarker
|
disease |
BEFREE |
Synergistic effect of therapeutic stem cells expressing cytosine deaminase and interferon-beta via apoptotic pathway in the metastatic mouse model of breast cancer.
|
26716512 |
2016 |
|
Malignant neoplasm of breast
|
0.560 |
Biomarker
|
disease |
BEFREE |
An in vivo assay performed using MDA-MB-231/luc breast cancer mammary fat pad xenografts in immunodeficient mice resulted in 50% reduced tumor growth and increased long-term survival in HB1.F3.CD and HB1.F3.CD.IFN-β plus 5-FC treated mice relative to controls.
|
24141111 |
2014 |
|
Malignant neoplasm of breast
|
0.560 |
AlteredExpression
|
disease |
BEFREE |
In addition, cancer-associated fibroblasts (CAF) isolated from a breast cancer patient were also able to express TRAIL and IFN-β upon DNA and RNA stimulation.
|
27077807 |
2016 |
|
Malignant neoplasm of breast
|
0.560 |
Biomarker
|
disease |
BEFREE |
CAFs not expressing the interferon response genes also promoted the growth of the MCF-7 breast cancer cell line but this phenotype was independent of the type one fibroblast interferon ligand.
|
25884794 |
2015 |
|
Hepatitis B
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The IFN-β-Luc expression and level of hepatitis B virus surface Antigen (HBsAg) showed that DDX3 mediated by the 5-HT<sub>7</sub> agonist (AS-19) increased IFN-β expression and inhibited HBV replication.
|
31172579 |
2019 |
|
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
Inhibition of miR-3613-3p decreased relative expressions of IFN-α and IFN-β, HBV DNA copies, and increased the hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) levels, whereas miR-3613-3p overexpression reversed these changes in vitro and in vivo.
|
31201869 |
2019 |
|
Hepatitis B
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The reduction in HBV DNA levels by TRK-560 treatment was significantly higher than that by PEG-IFN-α2a treatment both <i>in vitro</i> and <i>in vivo</i> (<i>P</i> = 0.004 and <i>P</i> = 0.046, respectively), and intracellular HBV covalently closed circular DNA (cccDNA) reduction by TRK-560 treatment was also significantly higher than that by PEG-IFN-α2a treatment <i>in vivo</i> (<i>P</i> = 0.0495). cDNA microarrays and ELISA for CXCL10 production revealed significant differences between TRK-560 and PEG-IFN-α2a in the induction potency of interferon-stimulated genes.
|
28373196 |
2017 |
|
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
Quantitation and typing of serum hepatitis C virus RNA in patients with chronic hepatitis C treated with interferon-beta.
|
8244255 |
1993 |
|
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
Temporal treatment with interferon-beta prevents hepatocellular carcinoma in hepatitis B virus X gene transgenic mice.
|
18083266 |
2008 |
|
Hepatitis B
|
0.400 |
Therapeutic
|
disease |
CTD_human |
Interferon prevents formation of replication-competent hepatitis B virus RNA-containing nucleocapsids.
|
15994231 |
2005 |
|
Hepatitis B
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Exposure of trophoblast to HBV significantly induced the expression of TLR7 (P<0.001), TLR8 (P=0.005), MyD88 (P=0.004), interferon (IFN)-α (P=0.004), IFN-β (P<0.001) and interleukin (IL)-8 (P=0.001).
|
26315138 |
2015 |
|
Hepatitis B
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Ribavirin, alone and in combination with interferon-beta, decreased hepatitis B virus levels in most patients, and mean serum hepatitis B virus DNA and DNA polymerase levels at the end of treatment were approximately half of baseline levels (p < 0.05).
|
8340055 |
1993 |
|
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
Thus, the tupaia infection model of HBV clearly indicated the suppression of IFN-β at 31 wpi, which might have contributed to the establishment of chronic HBV infection.
|
28551415 |
2017 |
|
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
In contrast to hepatitis B virus, infection with hepatitis D virus induces a strong IFN-β/λ response in innate immune competent cell lines.
|
29524530 |
2018 |
|
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
This study included 24 hepatitis B e-antigen (HBeAg)-positive patients with chronic hepatitis B virus (HBV) genotype C infection who were treated with lamivudine alone for 16-32 weeks, then with both IFN-β and lamivudine for 4 weeks, and finally with IFN-β alone for 20 weeks.
|
25884105 |
2015 |
|
Hepatitis B
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Interferon β promoter stimulator 1 polymorphisms (IPS-1) regulate interferon (IFN) mediated viral clearance in hepatitis B virus (HBV) infection.
|
30930359 |
2019 |
|
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
Moreover, in HBV-carrier mice, 3p-HBx-siRNA more strongly inhibited HBV replication and promoted IFN production than HBx-siRNA in primary HBV(+) hepatocytes and, therefore, significantly decreased serum hepatitis B surface antigen and increased serum IFN-β.
|
21721030 |
2011 |
|
melanoma
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
Interferon-beta from melanoma cells suppresses the proliferations of melanoma cells in an autocrine manner.
|
12096926 |
2002 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
CXCL10 reduced melanoma cell proliferation in IFN-β-sensitive cells as well as resistant cells.
|
26102027 |
2015 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Treatment of human melanomas with IFN-beta + MEZ, and to a lesser extent with MEZ, results in growth suppression and induced or enhanced mda-7 expression.
|
8545104 |
1995 |
|
melanoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The melanoma differentiation associated gene, mda-6, which is identical to the P53-inducible gene WAF1/CIP1, encodes an M(r) 21,000 protein (p21) that can directly inhibit cell growth by repressing cyclin dependent kinases. mda-6 was identified using subtraction hybridization by virtue of its enhanced expression in human melanoma cells induced to terminally differentiate by treatment with human fibroblast interferon and the anti-leukemic compound mezerein (Jiang and Fisher, 1993).
|
7936668 |
1994 |